Australia’s Therapeutic Goods Administration (TGA) has approved the OncoSil™ medical device for use in patients with locally advanced pancreatic cancer.

• Device Function: A single-use brachytherapy device that delivers beta radiation directly into pancreatic tumours and is used alongside gemcitabine-based chemotherapy.
• Regulatory Status: The device has been included on the Australian Register of Therapeutic Goods (ARTG).
• Clinical Use: Intended for locally advanced pancreatic cancer cases where tumours are unresectable and used in combination with chemotherapy.

This summary is based on a news article issued by BioSpectrum Asia.

Image for illustrative purposes only. Source: Canva.

About Ehub365

For Corporate Clients, ehub365 division delivers critical insights into the ASEAN medical sector, covering investments, new services, and practitioner news. 

A member of 365Asia. Our additional group services are Health365, 365Asia, 健康365, 365Sehat, and 365MEC.